SCHEMBL9980406

SCHEMBL9980406

CC(C)(C)c1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.54
S1PR4 O95977 1/20 0.45
MAPT P10636 7/20 0.44
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
PKM P14618 2/20 0.44
SLC9A1 P19634 1/20 0.44
HPGD P15428 5/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 3/20 0.44
MEN1 O00255 3/20 0.44
KDM4E B2RXH2 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
GAA P10253 2/20 0.44
APAF1 O14727 1/20 0.44
THRB P10828 1/20 0.44
GALK1 P51570 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12529434 0.81 SLC9A1 (0.46) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL799954 0.78 ALDH1A1 (0.44) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL26781772 0.77 TSHR (0.38) ALDH1A1RAB9AHPGDKMT2AMEN1
SCHEMBL799583 0.77 KMT2A (0.44) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL10078955 0.77 AHR (0.45) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL12445324 0.77 GAA (0.51) MAPTALDH1A1SMN1; SMN2RAB9ASLC9A1
SCHEMBL18014746 0.77 SOS1 (0.63) SOS1S1PR4MAPTALDH1A1SMN1; SMN2
SCHEMBL13680451 0.77 SOS1 (0.58) SOS1S1PR4MAPTALDH1A1SMN1; SMN2
SCHEMBL28879185 0.76 SOS1 (0.57) SOS1S1PR4MAPTALDH1A1SMN1; SMN2
SCHEMBL29962351 0.76 SOS1 (0.57) SOS1S1PR4MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163791-B2 Imidazole derivatives that induce apoptosis and their therapeutic uses INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2012-04-24 US disclosed
US-7888118-B2 induces differentiation of myoblasts or muscle fiber into neuron cells; drug screening; useful for treatment of neurodegenerative disorders, such as stroke, spinal cord injury, Parkinson's and Alzheimer's diseases; 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole (Neurodazine 1) INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2011-02-15 US disclosed
US-20100184097-A1 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION INDUSTRY-ACADEMIC CORPORATION FOUNDATION, YONSEI UNIVERSITY (KR) 2010-07-22 US disclosed
US-7718685-B2 4,5-bis(4-methoxyphenyl)imidizole compound inducing differentiation of myoblasts or muscle fibers and pharmaceutical compositions including said compound INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2010-05-18 US disclosed
US-20100105726-A1 IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2010-04-29 US disclosed
US-20070123576-A1 Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105726-A1 IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES NFATC1, AIFM1, TP53 SOS1 4385/4885S1PR4 3883/4885MAPT 431/4885
US-20070123576-A1 Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation TNNC1, TNNI3, PYGM SOS1 2354/4885S1PR4 2409/4885MAPT 225/4885
US-20100184097-A1 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION MUSK, TNNI3, TNNC1 SOS1 1843/4885S1PR4 1334/4885MAPT 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.